<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-type="olc" bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-RIL25182-TY2-74-JGF"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 S755 IS: Finn Sawyer Access to Cancer Testing Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2025-02-26</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>119th CONGRESS</congress><session>1st Session</session><legis-num>S. 755</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20250226">February 26, 2025</action-date><action-desc><sponsor name-id="S318">Mr. Wicker</sponsor> (for himself and <cosponsor name-id="S311">Ms. Klobuchar</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSFI00">Committee on Finance</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To facilitate the development of treatments for cancers, and for other purposes.</official-title></form><legis-body style="OLC" display-enacting-clause="yes-display-enacting-clause" id="H43818E7EDC4947C4945BBB206A89D34E"><section section-type="section-one" id="HCE7BD7604AEC4AF0A73A6CD7A0F4A11C"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Finn Sawyer Access to Cancer Testing Act</short-title></quote>.</text></section><section commented="no" id="H37B1181A2ACF44F883262EC12B77A460"><enum>2.</enum><header>Coverage of cancer diagnostic and laboratory tests</header><subsection id="H6FF748F3C4E547AE997FB6A447B78361"><enum>(a)</enum><header>Medicare</header><paragraph commented="no" id="HAC333EB827ED4DBE8B72AD188B37847F"><enum>(1)</enum><header>Coverage</header><text display-inline="yes-display-inline">Section 1861 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x</external-xref>) is amended—</text><subparagraph commented="no" id="HA802DDB5444E42EE952C2496EBAB2295"><enum>(A)</enum><text>in subsection (s)(2)—</text><clause commented="no" id="HF1C170F422A6477ABEBFE572C6D960ED"><enum>(i)</enum><text>in subparagraph (JJ), by adding <quote>and</quote> at the end; and</text></clause><clause commented="no" id="H2AC5F3A7BD2845788DB1EF31871551EA"><enum>(ii)</enum><text>by adding at the end the following new subparagraph:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H05A9ABF2943F40388C9469F9AA9E2C9F"><subparagraph commented="no" id="HC876C94F1A8B4E0C9BE9354FC270933F" indent="up1"><enum>(KK)</enum><text display-inline="yes-display-inline">cancer diagnostic and laboratory tests (as defined in subsection (nnn)) furnished on or after the date that is 6 months after the date of the enactment of this subparagraph.</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block></clause></subparagraph><subparagraph commented="no" id="H9A058A817E814317ABDB4E5030393BDC"><enum>(B)</enum><text>by adding at the end the following new subsection:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HDA64D6600AE44608A59F72533E271461"><subsection commented="no" id="H440FFA518C0A470ABC08FE4831246564"><enum>(nnn)</enum><header>Cancer diagnostic and laboratory tests</header><paragraph commented="no" id="H398B15C2D96B4FE3A77F83A288B48E77"><enum>(1)</enum><header>In general</header><text>The term <term>cancer diagnostic and laboratory tests</term> means—</text><subparagraph commented="no" id="H091ECB6AD35847FBA53D318DDA3123EC"><enum>(A)</enum><text display-inline="yes-display-inline">microarray analysis, DNA sequencing, RNA sequencing, whole-exome sequencing, and other forms of next-generation sequencing furnished and reported by a clinical laboratory (as defined in section 353(a) of the Public Health Service Act); and</text></subparagraph><subparagraph commented="no" id="HFDEBC66FD4FF4517B0E74A15B2832E82"><enum>(B)</enum><text>explanation and interpretation of any analysis or sequencing described in subparagraph (A);</text></subparagraph><continuation-text continuation-text-level="paragraph">furnished to an individual diagnosed with cancer. </continuation-text></paragraph><paragraph commented="no" id="H464929F1BDAC40D4886C64701FEBF7D2"><enum>(2)</enum><header>Frequency</header><text>When an individual test as described in paragraph (1) reports out the same genetic content, it may only be furnished with respect to an individual diagnosed with a cancer—</text><subparagraph commented="no" id="HB6B068D178BC4CF8AB84F31CAEBD5E6F"><enum>(A)</enum><text>once upon the diagnosis of such cancer; </text></subparagraph><subparagraph commented="no" id="HA35622A31529492FBFBB20FDA39AE018"><enum>(B)</enum><text>once upon any recurrence of such cancer; and</text></subparagraph><subparagraph id="HD80370CBB43E48378DF84A4B0C7881ED"><enum>(C)</enum><text>as necessary for purposes of planning treatment or monitoring the progression of such cancer or the response of such cancer to treatment.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph commented="no" id="H2C380E86190941D1B815B3AB3853992B"><enum>(2)</enum><header>Payment</header><text>Section 1833 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395l">42 U.S.C. 1395l</external-xref>) is amended—</text><subparagraph id="HB218FAE4A1A342B5BB95F2C9BA22F58D"><enum>(A)</enum><text>in subsection (a)(1)—</text><clause commented="no" id="HA02D05F451E349C9BAF4C05DBC777131"><enum>(i)</enum><text>by striking <quote>and </quote> before <quote>(HH)</quote>; and</text></clause><clause commented="no" id="HA943B0268D024F80A08ABC3A647DBA06"><enum>(ii)</enum><text>by inserting the following before the semicolon: <quote>, and (II) with respect to cancer diagnostic and laboratory tests (as defined in section 1861(nnn)), the amount paid shall be an amount equal to 80 percent (or 100 percent, in the case of such tests for which payment is made on an assignment-related basis) of the lesser of the actual charge for the test or the amount that would have been determined for such test under section 1834A had such test been a clinical diagnostic laboratory test;</quote>; and</text></clause></subparagraph><subparagraph id="H00709863AA3C44A2BEFAB56A55260F09"><enum>(B)</enum><text>in subsection (b)—</text><clause id="H44CB21EAEAEA4AAAA415D40139AF5B55"><enum>(i)</enum><text>by striking <quote>, and (13)</quote> and inserting <quote>(13)</quote>; and</text></clause><clause id="H0CA7C75700854C24BAEFDF583D5392E4"><enum>(ii)</enum><text>by striking <quote>1861(n).</quote> and inserting <quote>section 1861(n), and (14) such deductible shall not apply with respect to cancer diagnostic and laboratory tests (as defined in section 1861(nnn))</quote>. </text></clause></subparagraph></paragraph><paragraph commented="no" id="H273F1C48429B4E6096F1DABF371961FA"><enum>(3)</enum><header>Exclusion modification</header><text>Section 1862(a)(1) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395y">42 U.S.C. 1395y(a)(1)</external-xref>) is amended—</text><subparagraph commented="no" id="H491EAB1E69284F9485078328815AAC64"><enum>(A)</enum><text>in subparagraph (O), by striking <quote>and</quote> at the end;</text></subparagraph><subparagraph commented="no" id="HA55E22EAF7B24FD99B902FF6987FD084"><enum>(B)</enum><text>in subparagraph (P), by striking the semicolon and inserting <quote>, and</quote>; and</text></subparagraph><subparagraph commented="no" id="H370AAB4FB6D046628F4B4CE52EA4A59F"><enum>(C)</enum><text>by adding at the end the following new subparagraph:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H2C0E9C1BD5BA473CB0C9A9FCADE60769"><subparagraph commented="no" id="H72B59B50CBB640FFA2E224B3CF6EEA68" indent="up1"><enum>(Q)</enum><text display-inline="yes-display-inline">in the case of cancer diagnostic and laboratory tests (as defined in section 1861(nnn)), which are performed more frequently than is covered under such section;</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph></subsection><subsection id="H01EA81A6C3534BF1BDB3296F47839ED8"><enum>(b)</enum><header>Medicaid</header><paragraph id="H5F00F685C8F2439598B2A6BA0E78A984"><enum>(1)</enum><header>Inclusion as medical assistance</header><text display-inline="yes-display-inline">Section 1905(a) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396d">42 U.S.C. 1396d(a)</external-xref>) is amended—</text><subparagraph id="HD3F143BD6B584EB5870CBC757C9D8593"><enum>(A)</enum><text>in paragraph (31), by striking <quote>and</quote> at the end;</text></subparagraph><subparagraph id="HD677312B3C7C490696A4A5B762E507A1"><enum>(B)</enum><text>by redesignating paragraph (32) as paragraph (33); and</text></subparagraph><subparagraph id="HBF569B0C4FE546979F2FBCD11A2C9F73"><enum>(C)</enum><text>by inserting after paragraph (31) the following new paragraph:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HA7ABE2A100094B6FB8139BBC224F731D"><paragraph id="H642A95C90090430EB7512542744EB849"><enum>(32)</enum><text display-inline="yes-display-inline">cancer diagnostic and laboratory tests (as defined in section 1861(nnn)); and</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="H03BE3D6547754D35A2CB496E746EBEE7"><enum>(2)</enum><header>Mandatory coverage</header><text>Section 1902(a)(10)(A) of such Act is amended, in the matter preceding clause (i), by striking <quote>and (30)</quote> and inserting <quote>(30), and (32)</quote>.</text></paragraph><paragraph id="H9E9A6A0554184FCFAC70CB42232634FB"><enum>(3)</enum><header>Inclusion in benchmark coverage</header><text display-inline="yes-display-inline">Section 1937(b)(5) of such Act is amended by inserting before the period at the end the following: <quote>, and beginning January 1, 2027, coverage of cancer diagnostic and laboratory tests (as defined in section 1861(nnn))</quote>.</text></paragraph><paragraph id="id5D1E4743F61240E69965461198854AE9"><enum>(4)</enum><header>Effective date</header><subparagraph id="H0BBC355C16C04A499BC0677406D60364"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">The amendments made by this section shall apply with respect to items and services furnished on or after January 1, 2027.</text></subparagraph><subparagraph id="H4536282B75A54D57ADA94240AA894D43"><enum>(B)</enum><header>Exemption for State legislation</header><text display-inline="yes-display-inline">In the case of a State plan under title XIX of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396">42 U.S.C. 1396 et seq.</external-xref>), or waiver of such plan, that the Secretary of Health and Human Services determines requires State legislation in order for the respective plan to meet any requirement imposed by amendments made by this section, the respective plan shall not be regarded as failing to comply with the requirements of such title solely on the basis of its failure to meet such an additional requirement before the first day of the first calendar quarter beginning after the close of the first regular session of the State legislature that begins after the date of the enactment of this Act. For purposes of the previous sentence, in the case of a State that has a 2-year legislative session, each year of the session shall be considered to be a separate regular session of the State legislature.</text></subparagraph></paragraph></subsection><subsection id="HC01E09E5BCF84E4FBC3B1E45B81D8255"><enum>(c)</enum><header>CHIP</header><text>Section 2103(c) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1397cc">42 U.S.C. 1397cc(c)</external-xref>) is amended by adding at the end the following new paragraph:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HB8DDDB63E7D74BBA9E80641DEB2C576B"><paragraph id="H5A3669DB39E64726B6BD4977AFA7B2E2"><enum>(13)</enum><header>Coverage of cancer diagnostic and laboratory tests</header><text display-inline="yes-display-inline">Regardless of the type of coverage elected by a State under subsection (a), beginning January 1, 2025 child health assistance provided under such coverage for targeted low-income children and, in the case that the State elects to provide pregnancy-related assistance under such coverage pursuant to section 2112, such pregnancy-related assistance for targeted low-income pregnant women (as defined in section 2112(d)), shall include coverage of cancer diagnostic and laboratory tests (as defined in section 1861(nnn)). </text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section><section id="H48BF7DC6A9FA4FC89CCCEA385F10F2E4"><enum>3.</enum><header>Education and awareness program on genomic testing</header><subsection id="HE52CAE159CB64EAABBAC36DACC91DA7E"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services, in coordination with the Director of the National Human Genome Research Institute, shall carry out an education and awareness program for physicians and the general public on what genomic testing is, how it can be used, and the role of genetic counselors.</text></subsection><subsection id="HDEC561C14A924C7EADD5C5E87501E07F"><enum>(b)</enum><header>Cancer and molecular diagnostics</header><text display-inline="yes-display-inline">The education and awareness program under subsection (a) shall encourage the inclusion in graduate medical education and continuing medical education (including for specialty oncology services) of education and training on the importance of molecular diagnostics at diagnosis and reoccurrence of cancer to detect mutations.</text></subsection></section></legis-body></bill> 

